PARTNERS – Platform adaptive randomized trial for new and repurposed Filovirus treatments – Core Trial Protocol

Overview

The PARTNERS trial is the WHO sponsored international adaptive platform trial evaluating new and repurposed therapeutics for filovirus diseases, including Ebola and Marburg virus disease. The study aims to rapidly generate high-quality evidence on the safety and efficacy of promising treatments during outbreaks, while embedding research within frontline outbreak response activities. Demonstration of safety and efficacy of potential treatments in a trial, allows these drugs to become licensed, and made widely available to patients who may need them.

PARTNERS is conducted through close collaboration between national health authorities, research institutions, outbreak response partners, and international organizations. The protocol is designed to allow flexibility across different viruses, countries, and treatment strategies, enabling rapid adaptation as outbreaks evolve and new therapeutic candidates emerge.